article Open AccessTop 1% cited
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Journal of Clinical Oncology · 2004 · Vol. 22(11) · pp. 2184–2191
David H. Johnson✉(Baylor University Medical Center)Louis Fehrenbacher(Baylor University Medical Center)William Novotny(Baylor University Medical Center)Roy S. Herbst(Baylor University Medical Center)John Nemunaitis(Baylor University Medical Center)David M. Jablons(Baylor University Medical Center)Corey J. Langer(Baylor University Medical Center)Russell F. DeVore(Baylor University Medical Center)Jacques Gaudreault(Baylor University Medical Center)Lisa A. Damico(Baylor University Medical Center)Eric Holmgren(Baylor University Medical Center)Fairooz F. Kabbinavar(Baylor University Medical Center)
Abstract
Bevacizumab in combination with carboplatin and paclitaxel improved overall response and time to progression in patients with advanced or recurrent non-small-cell lung cancer. Patients with nonsquamous cell histology appear to be a subpopulation with improved outcome and acceptable safety risks.
Lung Cancer Treatments and MutationsPeptidase Inhibition and AnalysisLung Cancer Diagnosis and TreatmentCarboplatinMedicineBevacizumabPaclitaxelLung cancerInternal medicineOncologyChemotherapyResponse Evaluation Criteria in Solid TumorsPhases of clinical research
MeSH terms
BevacizumabAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungDose-Response Relationship, DrugFemaleHumansLung NeoplasmsMaleProportional Hazards ModelsSurvival AnalysisCarboplatinPaclitaxelAntibodies, Monoclonal, Humanized
Citations
1,949
FWCI
97.86
field-weighted impact
References
25
Percentile
100%
vs. same field & year
Citations per year
Cited by
A comparative analysis of P40 and P63 immunomarkers for differentiation of squamous cell carcinoma and adenocarcinoma, lung
International Journal of Clinical and Diagnostic Pathology · 2020 · 0 citations
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Journal of Clinical Oncology · 2008 · 3,206 citations
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
Journal of Clinical Oncology · 2008 · 2,958 citations
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Journal of Clinical Oncology · 2009 · 2,431 citations
Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma
Human Pathology · 2009 · 330 citations
Prevention of Venous Thromboembolism
CHEST Journal · 2004 · 5,881 citations
Prevention of Venous Thromboembolism
CHEST Journal · 2008 · 3,792 citations
Mechanisms of adverse effects of anti-VEGF therapy for cancer
British Journal of Cancer · 2007 · 967 citations
References
The biology of VEGF and its receptors
Nature Medicine · 2003 · 9,519 citations
Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
Biochemical and Biophysical Research Communications · 1989 · 2,262 citations
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Journal of Clinical Oncology · 1989 · 1,881 citations
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
Journal of Clinical Oncology · 2000 · 2,183 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.